BLFS
BioLife Solutions Inc manufactures proprietary and generic cGMP biopreservation media products, generic formulations of blood stem cell freezing media products, custom product formulation packaging services and contract aseptic manufacturing formulation.
BioLife Solutions Inc (BLFS) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Value (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | D+ (1.8) | C+ (2.7) | B- (2.9) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-10 | D+ (1.8) | C+ (2.7) | B- (2.9) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-03 | D+ (1.8) | C+ (2.7) | B- (2.9) | C+ (2.5) | F (0.0) | C- (2.0) |
| 2026-10-27 | D+ (1.8) | C+ (2.6) | B- (2.9) | C+ (2.5) | F (0.0) | C- (2.0) |
| 2026-10-20 | D+ (1.8) | C+ (2.6) | B- (2.9) | C+ (2.5) | F (0.0) | C- (2.0) |